Sentinel Oncology enters exclusive collaboration with PharmaEngine Inc for SOL578
Cambridge, UK, November 26th, 2020 – Sentinel Oncology Limited today announced that it has entered into a collaboration and license agreement with Taiwan based pharmaceutical company PharmaEngine, Inc. (TWO: 4162) to advance the development of SOL-578 , their checkpoint kinase 1 (Chk1) inhibitor. Under the terms of the agreement, PharmaEngine will fund IND enabling studies for SOL-578.
Sentinel Oncology Limited is a drug discovery company passionate about the development of novel therapeutics to treat cancer patients for whom there is currently an unmet medical need. The company’s mission is to increase survival and improve outcomes for cancer patients with CNS tumors. SOL-578 is a best-in-class checkpoint kinase 1 (Chk1) inhibitor featuring high kinase selectivity and oral bioavailability which targets the DNA Damage Response (DDR) network.
Under the terms of the Agreement, Sentinel Oncology will receive an exclusivity payment and PharmaEngine will obtain an option to receive the exclusive rights to develop and commercialize SOL-578 worldwide. In the event that PharmaEngine completes the IND enabling studies and exercise its option, Sentinel Oncology will be eligible to receive an upfront and development milestone payments in addition to tiered royalties based on future worldwide net sales of SOL-578.
Robert Boyle, CEO of Sentinel Oncology commented: “We are very excited about the prospects for this programme and the collaboration with PharmaEngine will enable SOL-578 to reach clinical trials and provide a real benefit for patients for whom there is currently a poor prognosis”.